IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
CD34 expression on bone marrow blasts is a novel predictor of poor prognosis independent of FlT3-ITD in acute myeloid leukemia with the NPM1-mutation
Zhu, Hong-Hu; Liu, Yan-Rong; Jiang, Hao; Lu, Jin; Qin, Ya-Zhen; Jiang, Qian; Bao, Li; Ruan, Guo-Rui; Jiang, Bin; Huang, Xiaojun
关键词Acute Myeloid Leukemia Nucleophosmin Mutation Cd34 Prognosis Flt3-itd
刊名LEUKEMIA RESEARCH
2013-06-01
DOI10.1016/j.leukres.2013.02.007
37期:6页:624-630
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Hematology
资助者Ministry of Health ; Beijing Municipal Science &amp ; Technology commission "Health care of Beijing citizens" ; Special-funded programme on national key scientific instruments and equipment development ; Ministry of Health ; Beijing Municipal Science &amp ; Technology commission "Health care of Beijing citizens" ; Special-funded programme on national key scientific instruments and equipment development
研究领域[WOS]Oncology ; Hematology
关键词[WOS]ACUTE MYELOGENOUS LEUKEMIA ; INTERNAL TANDEM DUPLICATION ; MINIMAL RESIDUAL DISEASE ; NORMAL KARYOTYPE ; FAVORABLE PROGNOSIS ; NUCLEOPHOSMIN NPM1 ; ELDERLY-PATIENTS ; GENE-MUTATIONS ; ADULT PATIENTS ; AML
英文摘要

To explore the prognostic value of CD34 expression in NPM1-mutated acute myeloid leukemia (NPM1m + AML), seventy-one NPM1m + AML patients were retrospectively analyzed. The patients with >7% CD34 expression (according to the ROC analysis) had a lower complete remission (CR) rate after 1 course of induction, disease-free survival (DFS), and overall survival (OS) compared to those with <= 7% CD34 expression (p = 0.0038; p = 0.001; p < 0.0001). A multivariate analysis revealed that CD34 expression is a prognostic factor that is independent of FlT3-ITD for relapse, DFS and OS. We established a novel prognostic model based on the CD34 and FLT3 status at diagnosis, which could facilitate the segregation of patients into three prognostically different subgroups. We demonstrate that CD34 expression on blasts is a novel, poor predictor independent of FlT3-ITD in NPM1-mutated patients and established a new prognostic model based on the CD34 and FLT3 status at diagnosis, which may facilitate immediate clinical utility for prognostic stratification and risk-adapted therapeutic choices. (C) 2013 Elsevier Ltd. All rights reserved.

语种英语
所属项目编号Z111107067311070 ; 2011YQ03013407
资助者Ministry of Health ; Beijing Municipal Science &amp ; Technology commission "Health care of Beijing citizens" ; Special-funded programme on national key scientific instruments and equipment development ; Ministry of Health ; Beijing Municipal Science &amp ; Technology commission "Health care of Beijing citizens" ; Special-funded programme on national key scientific instruments and equipment development
WOS记录号WOS:000318904600007
引用统计
被引频次:11[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/50900
专题北京大学第二临床医学院_血液科
作者单位Peking Univ, Inst Hematol, Peking Univ Peoples Hosp, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Zhu, Hong-Hu,Liu, Yan-Rong,Jiang, Hao,et al. CD34 expression on bone marrow blasts is a novel predictor of poor prognosis independent of FlT3-ITD in acute myeloid leukemia with the NPM1-mutation[J]. LEUKEMIA RESEARCH,2013,37(6):624-630.
APA Zhu, Hong-Hu.,Liu, Yan-Rong.,Jiang, Hao.,Lu, Jin.,Qin, Ya-Zhen.,...&Huang, Xiaojun.(2013).CD34 expression on bone marrow blasts is a novel predictor of poor prognosis independent of FlT3-ITD in acute myeloid leukemia with the NPM1-mutation.LEUKEMIA RESEARCH,37(6),624-630.
MLA Zhu, Hong-Hu,et al."CD34 expression on bone marrow blasts is a novel predictor of poor prognosis independent of FlT3-ITD in acute myeloid leukemia with the NPM1-mutation".LEUKEMIA RESEARCH 37.6(2013):624-630.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhu, Hong-Hu]的文章
[Liu, Yan-Rong]的文章
[Jiang, Hao]的文章
百度学术
百度学术中相似的文章
[Zhu, Hong-Hu]的文章
[Liu, Yan-Rong]的文章
[Jiang, Hao]的文章
必应学术
必应学术中相似的文章
[Zhu, Hong-Hu]的文章
[Liu, Yan-Rong]的文章
[Jiang, Hao]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。